{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:40:41Z","timestamp":1790307641272,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10637-023-01375-2","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T02:02:10Z","timestamp":1686794530000},"page":"556-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Yongzhao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"6","key":"1375_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"1375_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","volume":"52","author":"L Osmani","year":"2018","unstructured":"Osmani L, Askin F, Gabrielson E, Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol 52:103\u2013109. https:\/\/doi.org\/10.1016\/j.semcancer.2017.11.019","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"1375_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ (2019) Systemic therapy for locally advanced and metastatic non\u2013small cell lung cancer: a review. JAMA 322(8):764. https:\/\/doi.org\/10.1001\/jama.2019.11058","journal-title":"JAMA"},{"issue":"12","key":"1375_CR4","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC et al (2017) Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23(12):3012\u20133024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2554","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1375_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM et al (2018) STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS -Mutant Lung Adenocarcinoma. Cancer Discov 8(7):822\u2013835. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0099","journal-title":"Cancer Discov"},{"issue":"10","key":"1375_CR6","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","volume":"5","author":"F Wang","year":"2019","unstructured":"Wang F, Zhao Q, Wang YN et al (2019) Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple Cancer types. JAMA Oncol 5(10):1504. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2963","journal-title":"JAMA Oncol"},{"issue":"2","key":"1375_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001315","volume":"8","author":"H Bai","year":"2020","unstructured":"Bai H, Duan J, Li C et al (2020) EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma. J Immunother Cancer 8(2):e001315. https:\/\/doi.org\/10.1136\/jitc-2020-001315","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1375_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s40425-019-0737-3","volume":"7","author":"HX Wu","year":"2019","unstructured":"Wu HX, Chen YX, Wang ZX et al (2019) Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. J Immunother Cancer 7(1):264. https:\/\/doi.org\/10.1186\/s40425-019-0737-3","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1375_CR9","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","volume":"31","author":"D Marinelli","year":"2020","unstructured":"Marinelli D, Mazzotta M, Scalera S et al (2020) KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol 31(12):1746\u20131754. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2105","journal-title":"Ann Oncol"},{"issue":"14","key":"1375_CR10","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-19-3976","volume":"26","author":"K Zhang","year":"2020","unstructured":"Zhang K, Hong X, Song Z et al (2020) Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC. Clin Cancer Res 26(14):3649\u20133661. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3976","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1375_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40364-020-00241-0","volume":"8","author":"R Zhang","year":"2020","unstructured":"Zhang R, Wu HX, Xu M, Xie X (2020) KMT2A\/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors. Biomark Res 8(1):71. https:\/\/doi.org\/10.1186\/s40364-020-00241-0","journal-title":"Biomark Res"},{"issue":"1","key":"1375_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13073-018-0605-7","volume":"10","author":"JR Conway","year":"2018","unstructured":"Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E (2018) Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med 10(1):93. https:\/\/doi.org\/10.1186\/s13073-018-0605-7","journal-title":"Genome Med"},{"issue":"1","key":"1375_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/0008-5472.CAN-05-3014","volume":"66","author":"TK Bera","year":"2006","unstructured":"Bera TK, Fleur AS, Lee Y et al (2006) POTE Paralogs are Induced and differentially expressed in many cancers. Cancer Res 66(1):52\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3014","journal-title":"Cancer Res"},{"issue":"11","key":"1375_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41419-019-2046-7","volume":"10","author":"Z Shen","year":"2019","unstructured":"Shen Z, Feng X, Fang Y et al (2019) POTEE drives colorectal cancer development via regulating SPHK1\/p65 signaling. Cell Death Dis 10(11):863. https:\/\/doi.org\/10.1038\/s41419-019-2046-7","journal-title":"Cell Death Dis"},{"key":"1375_CR15","doi-asserted-by":"publisher","unstructured":"Wang Q, Li X, Ren S et al (2015) Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer. Coleman WB, ed. PLOS One 10(4):e0122792. https:\/\/doi.org\/10.1371\/journal.pone.0122792","DOI":"10.1371\/journal.pone.0122792"},{"issue":"3","key":"1375_CR16","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3892\/or.2014.3277","volume":"32","author":"N Cine","year":"2014","unstructured":"Cine N, Baykal AT, Sunnetci D, Canturk Z, Serhatli M, Savli H (2014) Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer. Oncol Rep 32(3):1078\u20131086. https:\/\/doi.org\/10.3892\/or.2014.3277","journal-title":"Oncol Rep"},{"issue":"9","key":"1375_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","volume":"50","author":"D Miao","year":"2018","unstructured":"Miao D, Margolis CA, Vokes NI et al (2018) Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 50(9):1271\u20131281. https:\/\/doi.org\/10.1038\/s41588-018-0200-2","journal-title":"Nat Genet"},{"issue":"6230","key":"1375_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science 348(6230):124\u2013128. https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"issue":"5","key":"1375_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H et al (2018) Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33(5):843-852e4. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.018","journal-title":"Cancer Cell"},{"issue":"2","key":"1375_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T et al (2018) Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of Cancer. Cell 173(2):291-304e6. https:\/\/doi.org\/10.1016\/j.cell.2018.03.022","journal-title":"Cell"},{"issue":"4","key":"1375_CR21","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48(4):812-830e14. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023","journal-title":"Immunity"},{"issue":"379","key":"1375_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"W Roh","year":"2017","unstructured":"Roh W, Chen PL, Reuben A et al (2017) Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379):eaah3560. https:\/\/doi.org\/10.1126\/scitranslmed.aah3560","journal-title":"Sci Transl Med"},{"issue":"12","key":"1375_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"issue":"5","key":"1375_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS J Integr Biol 16(5):284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118","journal-title":"OMICS J Integr Biol"},{"issue":"2","key":"1375_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/scd.2007.0079","volume":"17","author":"TK Bera","year":"2008","unstructured":"Bera TK, Fleur AS, Ha D et al (2008) Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells. Stem Cells Dev 17(2):325\u2013332. https:\/\/doi.org\/10.1089\/scd.2007.0079","journal-title":"Stem Cells Dev"},{"key":"1375_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2021.103214","volume":"108","author":"A Jay","year":"2021","unstructured":"Jay A, Reitz D, Namekawa SH, Heyer WD (2021) Cancer testis antigens and genomic instability: more than immunology. DNA Repair 108:103214. https:\/\/doi.org\/10.1016\/j.dnarep.2021.103214","journal-title":"DNA Repair"},{"issue":"1","key":"1375_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12865-018-0285-5","volume":"20","author":"X Wang","year":"2019","unstructured":"Wang X, Li M (2019) Correlate tumor mutation burden with immune signatures in human cancers. BMC Immunol 20(1):4. https:\/\/doi.org\/10.1186\/s12865-018-0285-5","journal-title":"BMC Immunol"},{"issue":"6","key":"1375_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(02)00776-3","volume":"3","author":"J Bart","year":"2002","unstructured":"Bart J, Groen HJ, van der Graaf WT et al (2002) An oncological view on the blood\u2013testis barrier. Lancet Oncol 3(6):357\u2013363. https:\/\/doi.org\/10.1016\/S1470-2045(02)00776-3","journal-title":"Lancet Oncol"},{"issue":"2","key":"1375_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","volume":"5","author":"E Fratta","year":"2011","unstructured":"Fratta E, Coral S, Covre A et al (2011) The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 5(2):164\u2013182. https:\/\/doi.org\/10.1016\/j.molonc.2011.02.001","journal-title":"Mol Oncol"},{"issue":"1","key":"1375_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M et al (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype Relationships and Predictors of response to checkpoint blockade. Cell Rep 18(1):248\u2013262. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019","journal-title":"Cell Rep"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01375-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T08:02:53Z","timestamp":1692777773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01375-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01375-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the study is based on public data, the informed consent and ethical proof are not required. All authors give their consent to publish this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No authors have any conflict of interest or competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}